Cyclooxygenase 2 expression in serous tumors of the ovary

Pankaj K. Singhal, Gregory Spiegel, Deborah Driscoll, Kunle Odunsi, Shashikant Lele, Kerry J. Rodabaugh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This study was designed to investigate the expression of cyclooxygenase (COX)-2 in ovarian serous tumors (benign, borderline tumors, and carcinomas) and primary peritoneal serous carcinomas. Cases diagnosed between 1995 and 2001 were reviewed; 47 benign tumors, 6 borderline tumors, and 39 carcinomas were examined, as well as 12 normal ovaries that served as controls. Blocks were stained with anti COX-2 polyclonal antibody and staining was graded qualitatively. The staining intensity was assessed as weak (score of 1), moderate (score of 2), or strong (score of 3). Normal ovarian and tubal epithelium, inclusion cysts, benign serous tumors, and borderline tumors had a uniform score 3 staining pattern. Serous ovarian carcinomas had variable staining scores, tending to correlate with the level of tumor differentiation. Well-differentiated carcinomas had more intense COX-2 staining than poorly differentiated carcinomas, which had only weak COX-2 staining. The degree of COX-2 staining was not significantly related to overall survival. In conclusion, COX-2 expression is present in serous tumors, including benign tumors, borderline tumors, and carcinomas. Similar to the findings in other neoplasms, COX-2 expression is strongest in well-differentiated tumors and is much less evident in those that are poorly differentiated. The clinical utility of these findings is related to the potential role of nonsteroidal anti-inflammatory drugs, which are COX-2 inhibitors, in treating and/or preventing some forms of ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)62-66
Number of pages5
JournalInternational Journal of Gynecological Pathology
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Cyclooxygenase 2
Ovary
Carcinoma
Neoplasms
Staining and Labeling
Cyclooxygenase 2 Inhibitors
Cysts
Anti-Inflammatory Agents
Epithelium

Keywords

  • Cyclooxygenase 2
  • Immunohistochemistry
  • Ovarian carcinoma
  • Serous tumors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology

Cite this

Cyclooxygenase 2 expression in serous tumors of the ovary. / Singhal, Pankaj K.; Spiegel, Gregory; Driscoll, Deborah; Odunsi, Kunle; Lele, Shashikant; Rodabaugh, Kerry J.

In: International Journal of Gynecological Pathology, Vol. 24, No. 1, 01.01.2005, p. 62-66.

Research output: Contribution to journalArticle

Singhal, Pankaj K. ; Spiegel, Gregory ; Driscoll, Deborah ; Odunsi, Kunle ; Lele, Shashikant ; Rodabaugh, Kerry J. / Cyclooxygenase 2 expression in serous tumors of the ovary. In: International Journal of Gynecological Pathology. 2005 ; Vol. 24, No. 1. pp. 62-66.
@article{d1332daec33847079603d9a75275c2d3,
title = "Cyclooxygenase 2 expression in serous tumors of the ovary",
abstract = "This study was designed to investigate the expression of cyclooxygenase (COX)-2 in ovarian serous tumors (benign, borderline tumors, and carcinomas) and primary peritoneal serous carcinomas. Cases diagnosed between 1995 and 2001 were reviewed; 47 benign tumors, 6 borderline tumors, and 39 carcinomas were examined, as well as 12 normal ovaries that served as controls. Blocks were stained with anti COX-2 polyclonal antibody and staining was graded qualitatively. The staining intensity was assessed as weak (score of 1), moderate (score of 2), or strong (score of 3). Normal ovarian and tubal epithelium, inclusion cysts, benign serous tumors, and borderline tumors had a uniform score 3 staining pattern. Serous ovarian carcinomas had variable staining scores, tending to correlate with the level of tumor differentiation. Well-differentiated carcinomas had more intense COX-2 staining than poorly differentiated carcinomas, which had only weak COX-2 staining. The degree of COX-2 staining was not significantly related to overall survival. In conclusion, COX-2 expression is present in serous tumors, including benign tumors, borderline tumors, and carcinomas. Similar to the findings in other neoplasms, COX-2 expression is strongest in well-differentiated tumors and is much less evident in those that are poorly differentiated. The clinical utility of these findings is related to the potential role of nonsteroidal anti-inflammatory drugs, which are COX-2 inhibitors, in treating and/or preventing some forms of ovarian carcinoma.",
keywords = "Cyclooxygenase 2, Immunohistochemistry, Ovarian carcinoma, Serous tumors",
author = "Singhal, {Pankaj K.} and Gregory Spiegel and Deborah Driscoll and Kunle Odunsi and Shashikant Lele and Rodabaugh, {Kerry J.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.pgp.0000148337.77264.27",
language = "English (US)",
volume = "24",
pages = "62--66",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cyclooxygenase 2 expression in serous tumors of the ovary

AU - Singhal, Pankaj K.

AU - Spiegel, Gregory

AU - Driscoll, Deborah

AU - Odunsi, Kunle

AU - Lele, Shashikant

AU - Rodabaugh, Kerry J.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - This study was designed to investigate the expression of cyclooxygenase (COX)-2 in ovarian serous tumors (benign, borderline tumors, and carcinomas) and primary peritoneal serous carcinomas. Cases diagnosed between 1995 and 2001 were reviewed; 47 benign tumors, 6 borderline tumors, and 39 carcinomas were examined, as well as 12 normal ovaries that served as controls. Blocks were stained with anti COX-2 polyclonal antibody and staining was graded qualitatively. The staining intensity was assessed as weak (score of 1), moderate (score of 2), or strong (score of 3). Normal ovarian and tubal epithelium, inclusion cysts, benign serous tumors, and borderline tumors had a uniform score 3 staining pattern. Serous ovarian carcinomas had variable staining scores, tending to correlate with the level of tumor differentiation. Well-differentiated carcinomas had more intense COX-2 staining than poorly differentiated carcinomas, which had only weak COX-2 staining. The degree of COX-2 staining was not significantly related to overall survival. In conclusion, COX-2 expression is present in serous tumors, including benign tumors, borderline tumors, and carcinomas. Similar to the findings in other neoplasms, COX-2 expression is strongest in well-differentiated tumors and is much less evident in those that are poorly differentiated. The clinical utility of these findings is related to the potential role of nonsteroidal anti-inflammatory drugs, which are COX-2 inhibitors, in treating and/or preventing some forms of ovarian carcinoma.

AB - This study was designed to investigate the expression of cyclooxygenase (COX)-2 in ovarian serous tumors (benign, borderline tumors, and carcinomas) and primary peritoneal serous carcinomas. Cases diagnosed between 1995 and 2001 were reviewed; 47 benign tumors, 6 borderline tumors, and 39 carcinomas were examined, as well as 12 normal ovaries that served as controls. Blocks were stained with anti COX-2 polyclonal antibody and staining was graded qualitatively. The staining intensity was assessed as weak (score of 1), moderate (score of 2), or strong (score of 3). Normal ovarian and tubal epithelium, inclusion cysts, benign serous tumors, and borderline tumors had a uniform score 3 staining pattern. Serous ovarian carcinomas had variable staining scores, tending to correlate with the level of tumor differentiation. Well-differentiated carcinomas had more intense COX-2 staining than poorly differentiated carcinomas, which had only weak COX-2 staining. The degree of COX-2 staining was not significantly related to overall survival. In conclusion, COX-2 expression is present in serous tumors, including benign tumors, borderline tumors, and carcinomas. Similar to the findings in other neoplasms, COX-2 expression is strongest in well-differentiated tumors and is much less evident in those that are poorly differentiated. The clinical utility of these findings is related to the potential role of nonsteroidal anti-inflammatory drugs, which are COX-2 inhibitors, in treating and/or preventing some forms of ovarian carcinoma.

KW - Cyclooxygenase 2

KW - Immunohistochemistry

KW - Ovarian carcinoma

KW - Serous tumors

UR - http://www.scopus.com/inward/record.url?scp=11244305499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244305499&partnerID=8YFLogxK

U2 - 10.1097/01.pgp.0000148337.77264.27

DO - 10.1097/01.pgp.0000148337.77264.27

M3 - Article

C2 - 15626918

AN - SCOPUS:11244305499

VL - 24

SP - 62

EP - 66

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 1

ER -